Abilify: Uses, dosage, side effects, warnings & patient reviews

What is Abilify (Aripiprazole)?

Abilify (aripiprazole) is an atypical antipsychotic medication. Atypical antipsychotics, also referred to as second-generation antipsychotics, represent a class of drugs with distinct mechanisms and side effect profiles compared to older, typical antipsychotics.

The active ingredient, aripiprazole, is a dopamine partial agonist. It functions by modulating dopamine and serotonin activity in the brain, acting as a stabilizer rather than a complete blocker of dopamine D2 receptors. This unique mechanism of action differentiates it from many other antipsychotics.

Abilify is available in several formulations, including immediate-release oral tablets, orally disintegrating tablets, an oral solution, and a long-acting injectable (Abilify Maintena). Generic versions containing aripiprazole are also available.

How to Take Abilify

Administration of Abilify must strictly follow a healthcare provider’s prescription. Dosage is individualized based on the specific condition being treated, patient response, and tolerability.

Administration Guidelines

Oral tablets and solution are typically taken once daily, with or without food. The oral solution should be administered using the provided dosing cup. Orally disintegrating tablets should be placed on the tongue without water and allowed to dissolve completely. The long-acting injectable formulation (Abilify Maintena) is administered intramuscularly by a healthcare professional every four weeks.

Dosage Initiation and Titration

Treatment is usually initiated at a low dose to minimize side effects. The prescribing healthcare provider will determine a titration schedule if a dosage increase is necessary. Patients should not adjust their dose or stop taking Abilify without medical consultation due to the risk of symptom return or withdrawal effects.

Missed Dose

If a dose of oral Abilify is missed, it should be taken as soon as remembered unless it is close to the time of the next scheduled dose. In that case, the missed dose should be skipped. Patients should not take a double dose. For missed injections of the long-acting formulation, contact the prescribing healthcare provider immediately for guidance.

Side Effects of Abilify

All antipsychotic medications, including Abilify, can cause side effects. The frequency and severity vary among individuals.

What is Abilify Used For?

Abilify (aripiprazole) is approved by the U.S. Food and Drug Administration (FDA) for specific psychiatric conditions. It is used under medical supervision following a formal diagnosis.

FDA-Approved Uses

• Schizophrenia: Treatment of schizophrenia in adults and adolescents aged 13 to 17 years.
• Bipolar I Disorder: Treatment of acute manic and mixed episodes, and maintenance treatment, in adults and pediatric patients aged 10 to 17 years. Also used as an adjunct to lithium or valproate for maintenance in adults.
• Major Depressive Disorder (MDD): Adjunctive treatment to antidepressants for adults with MDD who have had an inadequate response to antidepressant therapy alone. This is a common application and relates to the augmentation strategy in depression treatment.
• Irritability Associated with Autism: Treatment of irritability associated with autistic disorder in pediatric patients aged 6 to 17 years.
• Tourette’s Disorder: Treatment of Tourette’s disorder in pediatric patients aged 6 to 18 years.

Off-Label Use

Aripiprazole may be prescribed off-label by a physician for other conditions not listed above, such as certain anxiety disorders or as augmentation in obsessive-compulsive disorder (OCD). Such use is based on physician judgment and available clinical evidence.

Important Safety Concerns and Considerations

Black Box Warning

Abilify carries a Boxed Warning, the strongest requirement by the FDA. It states that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify is not approved for the treatment of patients with dementia-related psychosis.

Metabolic Changes

Although the risk is generally lower compared to some other atypical antipsychotics, Abilify can cause metabolic alterations. These may include weight gain, hyperglycemia (which may be associated with diabetes mellitus exacerbation or onset), and dyslipidemia. Periodic monitoring of weight, blood glucose, and lipid profiles is recommended, as part of managing potential metabolic syndrome risk factors.

Tardive Dyskinesia (TD)

TD is a syndrome of potentially irreversible, involuntary, dyskinetic movements that can develop with treatment using antipsychotic drugs. The risk appears to be greater in elderly patients, particularly women, and with longer treatment duration and higher cumulative dose. If signs of TD appear, discontinuation of Abilify should be considered.

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but potentially fatal reaction to antipsychotic drugs. Clinical signs include hyperpyrexia, muscle rigidity, altered mental status, autonomic instability (irregular pulse or blood pressure), and elevated CPK. Immediate discontinuation and intensive medical treatment are required.

Impulse-Control Disorders

Compulsive or uncontrollable urges to gamble, binge eat, shop, or engage in sexual activity have been reported in patients taking aripiprazole. These urges stopped when the dose was reduced or the medication was discontinued. Patients and caregivers should be alert for the emergence of new or increased intense urges.

Critical Warnings for Abilify Use

Cerebrovascular Adverse Events in Elderly Dementia Patients

In placebo-controlled trials with elderly dementia patients, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with aripiprazole compared to placebo.

Suicidality in Children and Young Adults

Antidepressants, including when aripiprazole is used as an adjunctive treatment for depression, may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults. Close monitoring for clinical worsening, suicidality, or unusual changes in behavior is essential, especially during initial months of therapy or after dosage changes.

Orthostatic Hypotension

Abilify may cause orthostatic hypotension, possibly due to its alpha-adrenergic blocking activity. The risk is higher during initial dose titration and with specific patient factors (dehydration, cardiovascular disease, concomitant antihypertensives).

Leukopenia, Neutropenia, and Agranulocytosis

As with other antipsychotics, leukopenia and neutropenia have been reported during treatment with aripiprazole. Patients with a history of clinically significant low white blood cell count (WBC) or drug-induced leukopenia/neutropenia should have their complete blood count monitored regularly during the first few months of therapy.

Abilify Dosage Information

Dosage must be individualized. The following table summarizes recommended target doses for FDA-approved indications in adults. Pediatric dosing is weight-based and differs.

Important Administration Notes

• Initiation: Treatment is typically initiated at a lower dose to allow adjustment to the medication.
• Titration: Dose increases should not be made before 2 weeks, the time needed to achieve steady state.
• Maximum Dose: Doses above 30 mg/day for schizophrenia or bipolar disorder have not been shown to be more effective and are associated with a higher risk of certain side effects.
• Hepatic/Renal Impairment: No dosage adjustment is routinely recommended for mild to moderate impairment. Use in severe impairment has not been evaluated.
• CYP450 Considerations: Dosage adjustments are required when co-administered with strong CYP2D6 inhibitors, CYP3A4 inhibitors, or CYP3A4 inducers.

Drug Interactions with Abilify

Abilify is primarily metabolized by the liver enzymes CYP2D6 and CYP3A4. Concomitant use of drugs that affect these enzymes can significantly alter aripiprazole blood levels.

Additional Information

Storage and Handling

Store Abilify tablets, orally disintegrating tablets, and oral solution at room temperature (68°F to 77°F or 20°C to 25°C). The oral solution can be used for up to 6 months after opening. Keep all medications out of the reach of children and pets.

Cost and Generic Availability

Generic aripiprazole has been available in the United States for several years, which typically results in a significantly lower cost compared to the brand-name Abilify. Patients are encouraged to discuss generic options with their prescribing healthcare provider and pharmacist.

Reporting Side Effects

Patients and caregivers are encouraged to report negative side effects of prescription drugs to the FDA MedWatch program or the relevant national health authority. Reporting helps gather more information on the safety profile of medications.

References and Medical Sources

1. U.S. Food and Drug Administration (FDA). Abilify (aripiprazole) Prescribing Information. Revised October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021436s044s045,021713s035s036,021729s027s028,021866s029s030lbl.pdf
2. National Institute of Mental Health (NIMH). Mental Health Medications. https://www.nimh.nih.gov/health/topics/mental-health-medications
3. Kane, J.M., et al. “Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.” Journal of Clinical Psychiatry, 2002.
4. Drugs.com. Aripiprazole Professional Monograph. Updated November 2023. https://www.drugs.com/monograph/aripiprazole.html

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.